Table 2. Univariate analysis.

	RFI			RFS			DRFS
Characteristic	HR	P-value	95% CI	HR	P-value	95% CI	HR	P-value	95% CI
Age at diagnosisa	0.96	0.074	(0.93–1.00)	1.04	0.000	(1.02–1.07)	1.06	0.000	(1.04–1.08)
BMIb	1.03	0.336	(0.97–1.09)	1.01	0.467	(0.98–1.05)	1.00	0.845	(0.97–1.04)
Race/ethnicity
White	Ref.			Ref.			Ref.
Black	0.87	0.819	(0.25–2.99)	0.74	0.454	(0.33–1.64)	0.57	0.231	(0.22–1.44)
Others	1.06	0.919	(0.35–3.19)	1.31	0.378	(0.72–2.40)	1.31	0.395	(0.70–2.46)
Menopausal status
Post	Ref.			Ref.			Ref.
Pre	2.11	0.080	(0.91–4.90)	0.49	0.018	(0.27–0.89)	0.41	0.008	(0.21–0.79)
Stage
I	Ref.			Ref.			Ref.
II	2.64	0.085	(0.87–7.96)	0.94	0.822	(0.54–1.63)	0.85	0.572	(0.48–1.51)
III	1.85	0.422	(0.41–8.26)	1.2	0.628	(0.58–2.47)	1.14	0.735	(0.54–2.42)
Gradec
I–II	Ref.			Ref.			Ref.
III	0.8	0.718	(0.24–2.70)	0.69	0.280	(0.35–1.35)	0.61	0.157	(0.31–1.21)
Histology
Ductal	Ref.			Ref.			Ref.
Other	1.55	0.481	(0.46–5.24)	0.86	0.754	(0.35–2.15)	0.97	0.943	(0.39–2.42)
Hormone receptord
ER and PR, <1%	Ref.			Ref.			Ref.
ER/PR, 1–9 %	1.86	0.245	(0.65–5.26)	1.89	0.040	(1.03–3.45)	1.69	0.099	(0.91–3.17)
Chemotherapy
A+T	Ref.			Ref.			Ref.
A	0.35	0.160	(0.08–1.52)	1	0.990	(0.52–1.95)	1.05	0.889	(0.52–2.11)
Other	1.13	0.906	(0.15–8.52)	2.82	0.031	(1.10–7.25)	2.57	0.077	(0.90–7.33)
Not received	0.94	0.927	(0.27–3.24)	2.29	0.010	(1.22–4.29)	2.62	0.003	(1.38–4.97)
Hormone therapy
No	Ref.			Ref.
Yes	0.89	0.913	(0.12–6.66)	0.88	0.823	(0.27–2.80)	0.63	0.528	(0.15–2.61)
Surgerye
Lumpectomy	Ref.			Ref.
Mastectomy	0.89	0.787	(0.37–2.11)	0.83	0.470	(0.49–1.39)	0.90	0.689	(0.52–1.54)
Radiation
No	Ref.			Ref.
Yes	1.21	0.704	(0.45–3.29)	1.24	0.477	(0.68–2.24)	1.20	0.561	(0.65–2.23)
pCRf
Obtained	Ref.			Ref.			Ref.
Not obtained	1.07	0.928	(0.25–4.53)	2.64	0.082	(0.88–7.89)	3.26	0.061	(0.95–11.28)

Abbreviations: A=anthracycline-based chemotherapy; A+T=anthracycline- and taxane-based chemotherapy; BMI=body mass index; CI=confidence interval; DRFS=distant relapse-free survival; ER=oestrogen receptor; HR=hazard ratio; pCR=pathological complete response; PR=progesterone receptor; RFI=recurrence-free interval; RFS=recurrence-free survival; Ref.=reference value.

^aHR expressed per additional year.

^bAvailable for 860 patients.

^cAvailable for 864 patients.

^dAvailable for 623 patients.

^eAvailable for 864 patients.

^fAvailable for 328 patients.